Sensei biotherapeutics reports first quarter 2025 financial results and updates on clinical progress

- favorable clinical data in pd-(l)1 resistant patients - - dose expansion enrollment complete with full data expected by year-end 2025 - - cash runway into the second quarter of 2026 - boston, may 06, 2025 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. “this was a breakthrough quarter for sensei,” said john celebi, president and ceo.
SNSE Ratings Summary
SNSE Quant Ranking